54.50 -0.18 (-0.33%)
ABT
Stock Details
Last Trade:54.50 Change:-0.18 (-0.33%) Prev Close:54.68 Open: 54.84 Days Range:54.30 – 54.88 52 Week Range: 41.27 - 56.79 Volume:7372781 P/E: 14.77EPS:3.69
View AllRecent Alerts 03/17/10
Recent Alert on 03/15/10 at 9:36am
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories (NYSE: ABT) and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX (choline fenofibrate)... Read More
Recent Alert on 03/15/10 at 9:36am
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Recent Alert on 03/15/10 at 7:31am
Abbott's (ABT) Investigational MitraClip System Meets Primary Safety and Effectiveness Endpoints
Abbott's (ABT) Investigational MitraClip System Meets Primary Safety and Effectiveness Endpoints
Recent Alert on 03/15/10 at 7:31am
Abbott's (ABT) Investigational MitraClip System Meets Primary Safety and Effectiveness Endpoints
Abbott's (ABT) Investigational MitraClip System Meets Primary Safety and Effectiveness Endpoints
Recent Alert on 03/12/10 at 4:10pm
Top 10 News Items 3/8-3/12: Retails Sales Jump, AIG (AIG) Has Another Huge Sale, PotashCorp (POT) Raises Guidance, Citigroup (C) Surges
Top 10 News Items 3/8-3/12: Retails Sales Jump, AIG (AIG) Has Another Huge Sale, PotashCorp (POT) Raises Guidance, Citigroup (C) Surges
View AllRecent Press Releases
Press Release on 03/15/10 at 7:30am
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Press Release on 03/14/10 at 8:05am
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
Press Release on 03/14/10 at 8:00am
Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 03/14/10 at 7:41am
Abbott Buys Facet to Strengthen Biologics Capabilities, Pharma Pipeline
Abbott Buys Facet to Strengthen Biologics Capabilities, Pharma Pipeline
Blog Posts on 03/12/10 at 11:10am
Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...
Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...